LENZ Therapeutics, Inc.
LENZ•NASDAQ•Healthcare•Biotechnology

About LENZ Therapeutics

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOEvert Schimmelpennink
Founded2019
IPO DateJune 25, 2021
Employees11
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.lenz-tx.com
Phone858 925 7000
Address
201 Lomas Santa Fe Drive, Suite 300 Solana Beach, California 92075 United States

Corporate Identifiers

CIK0001815776
CUSIP52635N103
ISINUS52635N1037
EIN84-4867570
SIC2836

Leadership Team & Key Executives

Evert B. Schimmelpennink
President, Chief Executive Officer, Secretary and Director
James W. McCollum
Co-Founder and Director
Daniel R. Chevallard CPA
Chief Financial Officer
Marc G. Odrich M.D.
Chief Medical Officer
Domenick Porfidia
Vice President of Sales
David Choromanski
Vice President of Marketing
Shawn Olsson
Chief Commercial Officer
Melissa Rosness
Senior Vice President of Manufacturing Operations
Kris Gambelin
Senior Vice President of Regulatory and Clincal Operations